Cellular Biomedicine Group Upgraded to NASDAQ Global Market
April 10 2015 - 7:30AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases, today
announced that it received notice that the NASDAQ Listing
Qualifications Department has approved an application to upgrade
the listing of the Company's securities from the NASDAQ Capital
Market to the NASDAQ Global Market, effective with the opening of
business on April 10, 2015. The NASDAQ Global Market is the segment
for public companies that meet the higher listing standards of
NASDAQ with requirements that include market value, financial and
liquidity measurements and corporate governance standards.
"We are extremely pleased to upgrade to a higher tier market
which marks another corporate milestone for the Company," commented
Tony (Bizuo) Liu, Chief Financial Officer of Cellular Biomedicine
Group. "Our upgrade to the NASDAQ Global Market demonstrates
continued validation of the strong positive momentum of our cell
therapy platforms, the significant clinical pipeline opportunities
in front of us and our healthy balance sheet. We appreciate NASDAQ
for recognizing our strict adherence to corporate governance
standards and enabling the Company to raise our profile in the
investment community."
The Company's stock will continue to trade under the ticker
symbol "CBMG" after the upgrade.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and
immune cell projects are the result of research and development by
scientists and doctors from China and the United
States. Our flagship GMP facility in China, consisting of eight
independent cell production lines, is designed, certified and
managed according to U.S. standards. To learn more about
CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024